{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Menzies NA"],"funding":["NCATS NIH HHS","NCHHSTP CDC HHS"],"pagination":["75-83"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8633045"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33(1)"],"pubmed_abstract":["<h4>Background</h4>Effective targeting of latent tuberculosis infection (LTBI) treatment requires identifying those most likely to progress to tuberculosis (TB). We estimated the potential health and economic benefits of diagnostics with improved discrimination for LTBI that will progress to TB.<h4>Methods</h4>A base case scenario represented current LTBI testing and treatment services in the United States in 2020, with diagnosis via. interferon-gamma release assay (IGRA). Alternative scenarios represented tests with higher positive predictive value (PPV) for future TB but similar price to IGRA, and scenarios that additionally assumed higher treatment initiation and completion. We predicted outcomes using multiple transmission-dynamic models calibrated to different geographic areas and est"],"journal":["Epidemiology (Cambridge, Mass.)"],"pubmed_title":["The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease."],"pmcid":["PMC8633045"],"funding_grant_id":["U38 PS004649","U38 PS004644","UL1 TR001863","U38 PS004646"],"pubmed_authors":["Menzies NA","Salomon JA","Parriott A","Shete PB","Marks SM","Shrestha S","Hill AN","Cohen T","Dowdy DW"],"additional_accession":[]},"is_claimable":false,"name":"The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease.","description":"<h4>Background</h4>Effective targeting of latent tuberculosis infection (LTBI) treatment requires identifying those most likely to progress to tuberculosis (TB). We estimated the potential health and economic benefits of diagnostics with improved discrimination for LTBI that will progress to TB.<h4>Methods</h4>A base case scenario represented current LTBI testing and treatment services in the United States in 2020, with diagnosis via. interferon-gamma release assay (IGRA). Alternative scenarios represented tests with higher positive predictive value (PPV) for future TB but similar price to IGRA, and scenarios that additionally assumed higher treatment initiation and completion. We predicted outcomes using multiple transmission-dynamic models calibrated to different geographic areas and est","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-26T13:25:51.011Z","creation":"2025-04-06T14:14:13.134Z"},"accession":"S-EPMC8633045","cross_references":{"pubmed":["34669631"],"doi":["10.1097/EDE.0000000000001418","10.1097/ede.0000000000001418"]}}